DSpace Collection:

Twelve-Month Real-World Outcomes of Faricimab for Treatment-Naive Neovascular AMD in Australia

2026-02-01T00:00:00Z

Title: Twelve-Month Real-World Outcomes of Faricimab for Treatment-Naive Neovascular AMD in Australia Authors: Gillies, M.; Hashimoto, Y.; Nazari, R.; Arnold, J.; Wang, B.; Barry, R.; Ferrier, R.; Game, J.; Barthelmes, D. Abstract: Background: To provide insights into the effectiveness and safety of faricimab for treatment-naïve eyes with neovascular age-related macular degeneration (nAMD). Methods: A retrospective cohort study using a prospectively-designed registry. Treatment-naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023-Sep 2024 were included. Controls were treatment-naïve eyes starting with aflibercept 2 mg before 2022. Visual acuity (VA), macular neovascularisation activity, time to first inactivity, number of injections, injection intervals and number of visits at 12 months were investigated. Eyes treated with faricimab versus aflibercept 2 mg were compared using overlap weighting. The main outcome measure was the 12-month VA change. Results: Twenty-three practitioners treated 160 eyes with a 4-letter gain in VA (mean, 61.5-65.5 letters) and 48% attaining a dosing interval of ≥ 12 weeks, although 22% were still treated at < 8 weekly intervals. The small proportion (6.9%) of eyes switching to another agent had improved vision but were mostly active when switching off faricimab. Eyes received 7.2 injections (mean) at 7.4 visits (mean), receiving treatment at 98% of visits indicating a strongly proactive treatment regimen. Most (71%) lesions became inactive by 12 months with a mean time to inactivation of 10.3 weeks. Eyes starting faricimab had a significantly higher inactivation rate with more eyes reaching the last injection interval of ≥ 12 weeks than those starting aflibercept 2 mg. Conclusions: These findings indicate that faricimab is safe and effective for treatment-naive eyes with nAMD. Faricimab had a stronger effect on nAMD lesion activity than aflibercept 2 mg. Keywords: faricimab; neovascular age‐related macular degeneration; observational study; real‐world outcomes; vascular endothelial growth factor inhibitors.

Outcomes After Switching to Faricimab in Neovascular Age- Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry

2025-12-01T00:00:00Z

Title: Outcomes After Switching to Faricimab in Neovascular Age- Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry Authors: Hunt, A.; Hashimoto, Y.; Young, S.; Arnold, J.; Game, Justin; Hooper, C.; Field, A.; Barry, R.; Barthelmes, D; Gillies, M. Abstract: ABSTRACT Background We aimed to describe 1- year outcomes of eyes switched to faricimab from first- generation vascular endothelial growth factor VEGF inhibitors for neovascular age- related macular degeneration nAMD in routine care Methods Multicentre observational study of 383 eyes tracked in the Fight Retinal Blindness registry switched to faricimab from aflibercept 2 mg ranibizumab or bevacizumab between 1st January 1st August 2023 in Australia Results One- year completion rates were high 335 383 88 The proportion of choroidal neovascular CNV lesions graded as inactive increased from 39 at switch to 63 at 12 months p 0 01 Mean visual acuity 95 Confidence Interval decreased from 70 0 68 6 71 5 to 68 4 66 7 70 1 logarithm of the minimum angle of resolution letters both approx 6 12 Mean treat ment intervals increased from 7 2 to 10 5 weeks p 0 01 Eyes with active CNV at switch maintained mean VA 0 5 1 7 0 7 letters 50 were inactivated at 12 months Eyes with inactive CNV at switch lost 3 5 5 0 1 9 letters 15 had reactivation at 12 months Switchback occurred in 64 383 eyes 17 predominantly to aflibercept 2 mg that lost 1 9 letters without interval change at 12 months Adverse outcomes were in keeping with previous reports with no cases of occlusive retinal vasculitis Conclusions We found that faricimab inactivated a significant proportion of CNV lesions that had been active using 1st gener ation VEGF inhibitors with a significant extension of the treatment interval A small reduction in VA occurred in switchers and eyes not switched through the same period

Outlier ophthalmologists in the treatment of neovascular age-related macular degeneration with intravitreal therapy

2025-04-01T00:00:00Z

Title: Outlier ophthalmologists in the treatment of neovascular age-related macular degeneration with intravitreal therapy Authors: Hashimoto, Y. H.; Hunt, A.R.; Wells, J. M.; Banerjee, G.; Ferrier, R.; Barry, R.; Field, A.; Game, J.; Hooper, C. Y.; Barthelmes, D.; Gillies, M. C. Abstract: Background: To compare individual ophthalmologists grouped as outliers or non-outliers based on the mean 12-month visual acuity (VA) outcomes for their patients with neovascular age-related macular degeneration (nAMD). Methods: This prospectively designed database study included treatment-naïve eyes with nAMD starting vascular endothelial growth factor inhibitors between July 2018 and April 2023 in Australia. Ophthalmologists were classified into high outliers, non-outliers and low outliers with a funnel plot of the adjusted mean 12-month VA change. The number of injections, last injection interval and proportion of visits where choroidal neovascularisation was active were compared between the groups. Results: 38 ophthalmologists who treated a total of 1266 eyes (male, 35%; mean age, 81 years old) were classified into 1 high outlier, 34 non-outliers and 3 low outliers (mean VA change, 7.5, 5.1 and 2.5 letters, respectively). The high outlier gave significantly more injections than the non-outliers (mean, 8.6 vs 7.7; p<0.001), while the low outliers administered significantly fewer injections than the non-outliers (mean, 7.1 vs 7.7; p=0.009). The last injection interval was shortest in the high outlier's eyes (9.4 weeks), followed by non-outliers' (10.8 weeks; p=0.04 (vs high outlier's)) and low outliers' (11.8 weeks; p=0.22 (vs non-outliers')). The low outliers' patients had more visits with intraretinal fluid (59%) than non-outliers' (29%; p<0.001) and high outlier's patients (31%; p<0.001). Conclusion: The low outliers' eyes had fewer injections, a longer treatment interval and more visits with intraretinal fluid. Building a system through which low outliers are anonymously notified of their performance would help improve general quality of care.

The use of fundus photography in the emergency room-A review

2025-04-01T00:00:00Z

Title: The use of fundus photography in the emergency room-A review Authors: Browning, S. D.; Costello, J. M.; Dunn, H. P.; Fraser, C. L. Abstract: Purpose of review: The ocular fundus reveals a wealth of pathophysiological findings which should change patient management in the emergency room (ER). Traditional fundoscopy has been technically challenging and diagnostically inaccurate, but technological advances in non-mydriatic fundus photography (NMFP) have facilitated clinically meaningful fundoscopy. This review presents an update on the literature regarding NMFP and its application to the ER, illustrating pivotal publications and recent advances within this field. Recent findings: NMFP's application in the ER is demonstrably feasible and seamlessly integrates into emergency physicians' (EP) diagnostic workflows in a clinically meaningful and time efficient manner. The images of the ocular fundus (OF) generated by NMFP are consistently high quality, allowing a greater diagnostic accuracy to EP and ophthalmology interpreters alike. Digital NMFP images facilitate effective ophthalmology input via telemedicine to review the images in the ER. NMFP has been shown to change management decisions in the ER, improving patient and departmental outcomes. Interpretation of fundus images remains a medical education challenge, and early research highlights the potential for artificial intelligence (AI) image systems of NMFP to augment image interpretation in the ER. NMFP can change the ER approach to OF assessment, however the factors limiting its routine implementation need further consideration. There is potential for AI to contribute to NMFP image screening systems to augment EPs diagnostic accuracy.